Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM
Mandate

VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURKLINIKEN I KATRINEHOLM

April 22, 2014

Vinge has advised AniCura (formerly Djursjukhusgruppen) in connection with the acquisition of Djurkliniken i Katrineholm Aktiebolag. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Gustav Jönsson, Erik Claesson, Niclas Winnberg and Emelie Klefbeck.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026